Meeting
2021 ASCO Annual Meeting
Testing for mutations in BRCA1 and BRCA2 among ovarian cancer patients at a diverse academic medical center.
Authors
Caitlin Taylor
Emory University Hematology Medical Oncology-Fellowship Program, Atlanta, GA
Caitlin Taylor , Ryan Mooney , Yuan Liu , Yichun Cao , Elizabeth Sakach , Christine R. Tallo , Jane Lowe Meisel
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Prevention, Risk Reduction, and Hereditary Cancer
Track
Prevention, Risk Reduction, and Genetics
Sub Track
Germline Genetic Testing
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 10588)
DOI
10.1200/JCO.2021.39.15_suppl.10588
Abstract #
10588
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Beyond BRCA1 and BRCA2: Implementation of a multigene panel for the upfront testing of germline mutations in ovarian cancer.
First Author: Maria Beatriz Mira
Poster
2016 ASCO Annual Meeting
Incidence of germline mutations in risk genes including BRCA1/2 in consecutive ovarian cancer (OC) patients (AGO TR-1).
First Author: Philipp Harter
First Author: Emmanouil S. Saloustros
Poster
2023 ASCO Annual Meeting
Nivolumab plus ipilimumab (N+I) in patients (pts) with ovarian cancer (OC) with BRCA1/2 mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.
First Author: Charles Drescher